---
schema_version: "secwatch.filing_event.v1"
accession: "0001048477-22-000020"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-25T23:17:16.751430+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# BioMarin appoints Erin Burkhart as Chief Accounting Officer

## Summary
- Burkhart named Group VP, CAO effective May 2, 2022; succeeds Brian Mueller who remains CFO and principal financial officer.
- Burkhart joins from Eli Lilly where she held senior roles; CPA with public accounting background at Arthur Andersen and Deloitte.
- Compensation includes $400K salary, 45% cash incentive target, $250K sign-on bonus, $250K relocation bonus, and $1.5M equity awards (RSUs + options).
- Equity grants under 2017 Equity Incentive Plan; RSUs vest 25% annually, options vest monthly over 4 years with 1-year cliff.

## SEC filing metadata
- accession: 0001048477-22-000020
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000104847722000020/0001048477-22-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000104847722000020/bmrn-20220505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001048477-22-000020
- JSON: https://secwatch.observer/filing/0001048477-22-000020.json
- Plain text: https://secwatch.observer/filing/0001048477-22-000020.txt

## Key facts
- Executive change
  Erin Burkhart was appointed as Group Vice President, Chief Accounting Officer at BIOMARIN PHARMACEUTICAL INC.
  - Action: appointed
  - Role: Group Vice President, Chief Accounting Officer
  source text: On May 05, 2022., BioMarin Pharmaceutical Inc. (“BioMarin” or “the Company”) announced the appointment of Erin Burkhart as BioMarin’s Group Vice President, Chief Accounting Officer, effective May 2, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000104847722000020/0001048477-22-000020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.